GT Biopharma, Inc (GTBP)
| Market Cap | 469.92M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -28.30M |
| Shares Out | 4.39M |
| EPS (ttm) | -6.45 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $16.55 |
| Previous Close | $16.09 |
| Change ($) | 0.46 |
| Change (%) | 2.86% |
| Day's Open | 16.03 |
| Day's Range | 15.49 - 16.75 |
| Day's Volume | 648,849 |
| 52-Week Range | 3.90 - 17.48 |
Penny stocks are hot right now and these former low-priced names are reaching for new highs this month. The post Former Penny Stocks To Watch Making New Highs In May 2021 appeared first on Penny Stocks ...
In the latest trading session, OXIS International Inc. (GTBP) closed at $11.74, marking a +0.34% move from the previous day.
These biotech penny stocks have begun turning heads in April 2021 The post 3 Penny Stocks To Watch As Biotech Surges In April 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | Pe...
BEVERLY HILLS, Calif., April 26, 2021 /PRNewswire/ — GT Biopharma, Inc. (NASDAQ:… The post GT Biopharma Announces the Appointments of Gregory Berk, M.D.
BEVERLY HILLS, Calif., April 26, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's pro...
In the latest trading session, OXIS International Inc. (GTBP) closed at $9.64, marking a +0.63% move from the previous day.
List Of Penny Stocks To Watch Right Now The post Hot Penny Stocks To Watch In April 2021 If Biotech Is A Focus appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
BEVERLY HILLS, Calif., April 19, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's pro...
BEVERLY HILLS, Calif., April 12, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's pro...
BEVERLY HILLS, Calif., April 8, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's prop...
BEVERLY HILLS, Calif., March 29, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's pro...
GT Biopharma Inc (NASDAQ: GTBP) has reported updated interim data from Phase 1/2 clinical trial, evaluating the Company's lead candidate, GTB-3550, in high-risk myelodysplastic syndromes (MDS) and refra...
BEVERLY HILLS, Calif., March 17, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP) a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's prop...
BEVERLY HILLS, Calif., March 10, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP) a clinical stage biopharmaceutical company focused on the development and commercialization of disruptive, target-...
BEVERLY HILLS, Calif.--(BUSINESS WIRE)--GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage biopharmaceutical company focused on the development and commercialization of its disruptive, target-directed ...
BEVERLY HILLS, Calif.--(BUSINESS WIRE)--GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company's proprietary NK cell engager (TriKE™) ...
BEVERLY HILLS, Calif., Jan. 19, 2021 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company's proprietary NK cell enga...
BEVERLY HILLS, Calif., Dec. 28, 2020 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company's proprietary NK cell enga...
BEVERLY HILLS, Calif, Dec. 21, 2020 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company's proprietary NK cell engag...
BEVERLY HILLS, Calif., Dec. 17, 2020 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) a company focused on developing innovative therapeutic treatments based on its proprietary NK cell engager...
BEVERLY HILLS, Calif., Dec. 14, 2020 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company's proprietary NK cell enga...
With the pandemic drawing much attention toward biotech stocks, there are some interesting ideas among in the small-cap field, but only if you understand the severe risks involved. The post 7 Biotech Pe...
GT Biopharma (GTBP) news for Tuesday about it working on a possible treatment for the coronavirus from China has GTBP stock heading higher.
About GTBP
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. The company develops various immuno-oncology product candidates, including GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced sy... [Read more...]
| Industry Biotechnology | Founded 1965 |
| CEO Anthony Cataldo | Employees 3 |
| Stock Exchange NASDAQ | Ticker Symbol GTBP |
Analyst Forecasts
The average 12-month stock price forecast for GT Biopharma is 23.00, which is an increase of 38.97% from the latest price.